A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin
Latest Information Update: 17 Oct 2024
At a glance
- Drugs BCD 263 (Primary) ; Nivolumab
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Acronyms UNIVERSE
- Sponsors Biocad
- 17 Oct 2024 New trial record